FGFR2 and gastric cancer: Trials of the irreversible covalent binding FGFR inhibitors futibatinib (TAS-120, NCT04189445) and infigratinib (NCT05019794) for FGFR 1–4-rearranged solid tumours and FGFR2-amplified GC are also currently ongoing (Table 2).